Unlock First-Line Glaucoma Care with Voyager™ DSLT
Voyager™ DSLT is designed to automatically deliver 120 laser pulses directly through the limbus to the trabecular meshwork to improve aqueous outflow and reduce intraocular pressure.
Evolving First-Line Treatment Paradigm
The Laser in Glaucoma and Ocular Hypertension (LiGHT) study found that SLT is efficacious as a primary procedure for the treatment of OAG and OHT.1
Recognizes SLT as an effective primary intervention for OAG2
Recommends that SLT should be considered as an initial treatment option for mild or moderate OAG and OHT patients3
Recommends 360o SLT as first-line treatment for people with newly diagnosed OHT and COAG4
Exceptional Experience for the Patient and Physician
Introducing Voyager™ DSLT
“This technology will hopefully change hearts and minds about primary SLT in a way that manual SLT has not.”
Steven Sarkisian, M.D.
“The patient experience was amazing.”
Rob Melendez, M.D.
Effective IOP-Lowering with a Proven Safety Profile
Direct Selective Laser Trabeculoplasty (DSLT) in Open Angle Glaucoma (OAG) and Ocular Hypertension (OHT): A Randomized Controlled Trial (GLAUrious)5
Decreased Medication Burden
At 12 months5:
62%
of all DSLT patients
were medication-free
70%
of DSLT patients who entered the study medication-free, remained medication-free
81%
of DSLT patients were on the same or fewer medications
Proven Safety Profile with Low Rate of Adverse Events
In DSLT group5:
0
No ocular serious AEs as a result of the procedure through 12 months
1.0%
Extremely low rate of SSIs* for IOP control at 12 months
*Secondary Surgical Interventions
6.1%
Low rate of non-serious AEs at >6 months
Voyager™ DSLT Resources
2022 Journal of Glaucoma
Energy Dose-Response in Selective Laser Trabeculoplasty: A Review
Radcliffe N, et al.
2021 TVST – ARVO Journal
Automated Direct Selective Laser Trabeculoplasty: First Prospective Clinical Trial
Goldenfeld M, et al.
2021 British Journal of Ophthalmology
Direct selective laser trabeculoplasty in open angle glaucoma study design
Congdon N, et al.
Alcon Voyager™ DSLT Important Product Information
Caution: Federal (USA) law restricts this device to sale by, or on the order of, a physician.
Intended Use: Voyager™ DSLT is a prescription device intended for use in performing selective laser trabeculoplasty.
Indications: Voyager™ DSLT is indicated for use in selective laser trabeculoplasty (SLT).
Contraindications: Use of the Voyager™ DSLT device is contraindicated in the following patients:
• Patients who are unable to fixate their head and/or eyes, such as patients suffering from uncontrolled nystagmus, tremors or similar conditions.
•Patients with a pupil that cannot constrict to a diameter of 4 mm or less.
Warnings:
• Users should wear laser safety eyewear while performing a procedure with the Voyager DSLT device to avoid injury to the user’s eyes.
• Use of controls or adjustments or performance of procedures other than those specified herein may result in hazardous laser radiation exposure.
• Caution should be used when treating patients who have active uveitis or neovascularization that involves the iridocorneal angle with the Voyager DSLT device.
• The effect of selective laser trabeculoplasty energy on glaucoma implants located in the iridocorneal angle has not been studied. Because your version of the Voyager DSLT device does not allow masking of the implant area (i.e. ability to program a laser pattern which skips the local area of the implant), the use of the device is not recommended in eyes which have a glaucoma implant at any clock hour in the iridocorneal angle.
• In the pivotal clinical study of the Voyager DSLT device, the safety and effectiveness of re-treatment was not studied; therefore, the level of IOP reduction and potential for complications associated with re-treatment has not been established. Re-treatment is not recommended.
ATTENTION: Refer to the Voyager™ DSLT Directions for Use operating instructions and for the accessories/consumables and User Guide for a complete listing of indications, warnings, cautions and notes.
REFERENCES:
1. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial: Six-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension. Ophthalmology. 2023;130(2):139-151.
2. Takusagawa HL, Hoguet A, Sit AJ, et al. Selective laser trabeculoplasty for the treatment of glaucoma. Ophthalmology. 2024;131(1):37-47. doi:10.1016/j.ophtha.2023.07.029.
3. European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br J Ophthalmol. 2021;105(Suppl 1):1-169. doi:10.1136/bjophthalmol-2021-egsguidelines.
4. National Institute for Health and Care Excellence. Glaucoma: Diagnosis and Management. London: National Institute for Health and Care Excellence (NICE); 2022.
5. GLAUrious Study - Clinical Study Report (CSR). CA-RP-01-006, Rev. 01; 2022.
